Elixion has taken some important steps in the last few weeks with in silico validation of our quantum-based R&D process and the launch of our company website. After months of working quietly behind the scenes, we are now able to share what we have built and the vision that drives us forward.
Elixion was founded with one clear mission: to bring discoveries faster to the patients who need them most.
We are not a platform company. We are building a new class of therapeutic biotech, a precision-driven organisation that transforms advanced scientific principles into tangible medicines.
Our approach combines quantum physics, causal biology, multi-omics and native AI to understand the true mechanics of disease and design better drugs from the start. The goal is simple but transformative: to reduce the guesswork that has long slowed discovery and to make every experiment count.
Our work begins where unmet need and scientific opportunity meet, in oncology and immunology. Over just eleven months, and without external funding, our team has achieved in silico validation of targets for two closely related indications. This milestone demonstrates both ambition and discipline: focusing where our science can achieve depth, scale and impact, while enabling strong operational and economic efficiency for investors.
What sets Elixion apart, and has allowed us to achieve this so quickly, is the strength of our people and the way we work. Our scientific leaders bring experience from Oxford, Cambridge, Imperial College and other world-class institutions recognised for ambitious and rigorous science. Alongside them is a senior business team with global experience across pharma, biotech, investment banking and legal strategy.
This combination of deep science and disciplined execution ensures that every programme we advance is evaluated not only for its biological merit but also for its regulatory feasibility, commercial potential and investor value.
Zurich is the ideal home for Elixion. It is a stable, globally connected hub with a strong scientific ecosystem and a culture that values rigour and innovation. It allows us to grow with confidence, collaborate internationally and maintain operational excellence.
Elixion is still at the beginning of its journey, but we are building on firm ground: cutting-edge science, proof of precision and a team with the maturity to translate discovery into value. For our investors, that means transparency and disciplined growth. For our partners, collaboration rooted in trust. And for patients, the promise of truly transformative therapies.
I look forward to sharing our progress as we move from validation to impact.
Marco Piccinini
Chief Executive Officer & Co-Founder
Elixion BioTech AG